Figure 3: Overview of the TAIC-I trial. Patients enrolled in the TAIC-I Study each received a kidney transplant from a deceased donor. The mean age of the patients was 46.3 years and 9/12 patients were male. The median HLA-A,-B and -DR mismatch was 5/6. Initially, patients were treated with a combination of tacrolimus (trough levels of 10-15 ng/ml), sirolimus (trough levels of 4-8 ng/ml) and corticosteroids. Cells were infused on day 5 post-transplant. Steroids were tapered in weeks 5 and 6. Sirolimus was withdrawn in weeks 7 and 8. If graft function remained stable, tacrolimus treatment was first minimised to trough tacrolimus levels of 8-10 ng/ml by week 12 and then to levels of 5-8 ng/ml by week 24. Further reductions in tacrolimus therapy were undertaken in patients with stable graft function and no histological evidence of rejection. Figure reproduced with permission from Hutchinson, JA. et al. Transplant International (2008) 21:728-741.